Method for protecting vascular endothelial function by combining radix astragali and radix salviae miltiorrhizae qi-tonifying dropping pill with atorvastatin

Through the combined use of Qishen Yiqi Drip Pills and atorvastatin, the problem of major side effects of atorvastatin was solved, significantly reducing ET-1 in patients with hyperlipidemia, increasing NO, reducing vascular endothelial damage, and inhibiting thrombosis. , reduces the risk of cardiovascular events and provides a safe and effective treatment plan.

CN118976057APending Publication Date: 2024-11-19PEOPLES HOSPITAL OF INNER MONGOLIA AUTONOMOUS REGION
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411055051.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Although atorvastatin can improve the vascular endothelial function of patients with hyperlipidemia, its side effects are great, making it difficult to effectively reduce ET-1, increase NO and reduce vWF while avoiding other adverse reactions.

Method used

The combined use method of Qishen Yiqi Drip Pills and atorvastatin was used to record drug-related adverse reactions by random grouping and continuous use of drugs for 8-9 weeks, and the serum endothelin-1, NO, and Indicators such as vWF are statistically analyzed to determine the impact of different treatment methods.

Benefits of technology

Qishen Yiqidie Pills combined with atorvastatin are more effective in reducing ET-1, increasing NO and reducing vWF, especially in the later stage of treatment, which helps to reduce the risk of cardiovascular disease and reduce endothelial vascular Injure and inhibit thrombosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976057A_ABST
    Figure CN118976057A_ABST
Patent Text Reader

Abstract

The invention relates to the field of medical treatment, and discloses a method for protecting vascular endothelial functions by combining radix astragali and radix salviae miltiorrhizae qi-tonifying dripping pills with atorvastatin, which comprises the following steps: S1, selecting experimental subjects: selecting proper hyperlipidemia patients, and grouping; s2, attention is paid to the incorporation standards, wherein the medical experiment standards, the age standards and the compliance standards are met; s3, intervention measures: giving atorvastatin to the control group, and taking the atorvastatin according to medicine taking regulations of the control group; the test group A is given with radix astragali and radix codonopsis qi-tonifying dropping pills, and the pills are taken according to the medicine taking regulations of the group In the test group B, Qi-tonifying dripping pills containing radix astragali and radix salviae miltiorrhizae and atorvastatin are applied, the use method and the use amount are the same as those of the previous one, and each group is continuously applied for 8 weeks. Researches find that combined use of the qi-tonifying dripping pill containing radix astragali and radix salviae miltiorrhizae and atorvastatin is more effective in reducing the ET-1 level of a patient with hyperlipidemia than independent use of atorvastatin, and the curative effect of combined use of the qi-tonifying dripping pill containing radix astragali and radix salviae miltiorrhizae is gradually shown and continuously superior to that of independent use of atorvastatin from 2 weeks to 8 weeks of treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medical technology, and in particular to a method for protecting vascular endothelial function by combining Qishen Yiqi dripping pills with atorvastatin. Background Art

[0002] Endothelial cells are a group of cells covering the endothelium of blood vessels. They have endocrine function, anti-thrombotic effect and vascular tension regulation. Endothelial damage is the initiating factor of atherosclerosis. Protecting endothelial function is an effective way to block the occurrence and development of various vascular diseases. Many factors can cause endothelial damage, such as hyperlipidemia, hypertension, hyperglycemia, high homocysteine, high uric acid, smoking, etc. Studies have shown that endothelial damage caused by hyperlipidemia is closely related to the occurrence of cardiovascular diseases. Statins are currently the first choice for clinical treatment of hyperlipidemia. They have good efficacy in lowering lipids, improving atherosclerosis and preventing cardiovascular events. Studies have shown that atorvastatin can improve endothelial function in patients with hyperlipidemia, reduce ET-1, increase NO and reduce vWF. However, in recent years, concerns and debates about statins' muscle toxicity, liver damage, adverse reactions to the nervous system, new tumors and diabetes have never stopped.

[0003] In traditional Chinese medicine, vascular endothelium belongs to the category of pulse. The physiological dysfunction of the pulse can easily lead to a series of pathological changes such as blood stasis and phlegm coagulation. Phlegm and blood stasis lead to atherosclerosis. In traditional Chinese medicine, "the root is in qi and blood, and the symptoms are stasis", "replenishing qi and activating blood circulation" are the basic principles of treatment. Qishen Yiqi Drop Pills are a modern Chinese medicine developed based on the principle of "replenishing qi and activating blood circulation". They are composed of astragalus, salvia miltiorrhiza, Panax notoginseng, and dalbergia odorifera. Clinical studies have shown that Qishen Yiqi Drop Pills are beneficial to the long-term prognosis of patients with cardiovascular diseases. Pharmacological studies have shown that Qishen Yiqi Drop Pills can inhibit the occurrence and development of atherosclerosis from multiple pathways. Animal experiments have shown that Qishen Yiqi Drop Pills have a certain protective effect on the vascular endothelial function of hyperlipidemia rats.

[0004] Based on the above research foundation, we conducted a clinical study on the effect of Qishen Yiqi Drops combined with atorvastatin on vascular endothelial function in patients with hyperlipidemia, and compared it with atorvastatin alone and Qishen Yiqi Drops alone, in order to provide a reference for optimizing clinical treatment. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides a method for protecting vascular endothelial function by combining Qishen Yiqi Drop Pills with atorvastatin, which solves the problem that atorvastatin can improve vascular endothelial function in patients with hyperlipidemia, reduce ET-1, increase NO and reduce vWF, but has significant side effects.

[0006] To achieve the above objectives, the present invention is implemented by the following technical scheme: a method for protecting vascular endothelial function by combining Qishen Yiqi dripping pills with atorvastatin, characterized in that it comprises the following steps:

[0007] S1. Selection of experimental subjects: Appropriate patients with hyperlipidemia were selected and divided into groups. One-way analysis of variance and Fischer's exact test were used to compare the differences in basic demographic data between the groups.

[0008] S2. Pay attention to the inclusion criteria: meet the medical experiment criteria, meet the age criteria, meet the compliance criteria, and also pay attention to the exclusion criteria;

[0009] S3. Intervention measures: The control group was given atorvastatin according to the medication regulations of the control group; the experimental group A was given Qishen Yiqi dripping pills according to the medication regulations of group A; the experimental group B was given Qishen Yiqi dripping pills + atorvastatin, with the same usage and dosage as before, and each group took the medicine for 8-9 weeks;

[0010] S4. Observation indicators and detection methods: At enrollment, 2-3 weeks after administration, 4-5 weeks after administration, and 8-9 weeks after administration, extract patient characteristics and save them for future use, and use specific detection methods;

[0011] S5. Record reactions: Record drug-related adverse reactions during treatment;

[0012] S6. Statistical analysis: Data analysis was performed using SPSS and GraphPad Prism software. Two-factor repeated measures analysis of variance was used to determine the effects of different treatments on the index values ​​of the research subjects over time. P < 0.05 was considered statistically significant.

[0013] Preferably, in step S1, appropriate hyperlipidemia patients are selected and grouped as follows: 122-130 hyperlipidemia patients are selected and randomly divided into three groups, 40-42 cases in group A, 40-44 cases in group B, and 42-46 cases in group C.

[0014] Preferably, the basic demographic data mentioned in step S1 specifically include gender, age and basal blood lipid levels, and the comparison data need to be statistically insignificant and have baseline comparability.

[0015] Preferably, the medical experimental standards mentioned in step S2 specifically include: meeting the diagnostic standards for hyperlipidemia, being diagnosed with hyperlipidemia, and belonging to the Qi deficiency and blood stasis type through TCM differentiation.

[0016] Preferably, the age standard mentioned in step S2 is specifically: age 20-80 years old.

[0017] Preferably, the compliance standards mentioned in step S2 specifically include: having no contraindications to the drugs used in this study, good compliance, being able to cooperate in completing the study, and signing an informed consent form.

[0018] Preferably, the exclusion criteria mentioned in step S2 are specifically: severe liver and kidney dysfunction, autoimmune diseases, malignant tumors; allergic constitution.

[0019] Preferably, the medication regulations for the control group mentioned in step S3 are specifically: 20-30 mg each time, once a day, orally before bedtime; the medication regulations for group A mentioned in step S3 are specifically: 0.5-0.6 g each time, 3 times a day, half an hour after a meal.

[0020] Preferably, the extraction of patient characteristics and storage for later use mentioned in step S4 specifically comprises: drawing 5-6 ml of venous blood from the patient, centrifuging at 3000 r / min at 4°C for 10-15 min, separating and collecting serum, and storing it at -80--90°C for later use.

[0021] Preferably, the specific detection methods in step S4 include: determining serum endothelin-1, von Willebrand factor, thromboxane, and 6-keto-prostaglandin F-1a levels by ELISA; and determining serum NO levels by microplate reader.

[0022] The present invention provides a method for protecting vascular endothelial function by combining Qishen Yiqi Drop Pills with atorvastatin. The method has the following beneficial effects:

[0023] 1. The present invention has found through research that the combined use of Qishen Yiqi Dropping Pills and atorvastatin is more effective in reducing the ET-1 level in patients with hyperlipidemia than the use of atorvastatin alone. From 2 to 8 weeks of treatment, the therapeutic effect of the combined medication gradually emerges and continues to be better than that of atorvastatin alone. The effect of Qishen Yiqi Dropping Pills is also gradually stronger than that of atorvastatin.

[0024] 2. The present invention has shown through research that Qishen Yiqi Drop Pills and atorvastatin, used alone or in combination, can improve the vascular function of patients with hyperlipidemia, among which the combined use performs best in increasing NO levels and reducing ET-1, especially in the later stages of treatment, and helps reduce the risk of cardiovascular diseases.

[0025] 3. The present invention has shown through research that Qishen Yiqi Drop Pills and atorvastatin, used alone or in combination, can reduce the vWF level of patients with hyperlipidemia, among which the combined use has the most significant effect, which helps to reduce vascular endothelial damage and inhibit thrombosis, especially in the early and middle stages of treatment.

[0026] 4. The present invention has found through research that Qishen Yiqi Drop Pills and atorvastatin, used alone or in combination, can increase 6-Keto-PGF-1a in patients with hyperlipidemia, especially after 8 weeks of treatment, the combined use has a better effect and helps to improve vascular function and platelet aggregation. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 is a flow chart of the present invention;

[0028] Figure 2 It is a schematic diagram of each group of baseline data of the present invention;

[0029] Figure 3 This is a schematic diagram of the time points ET-1 of each component of the present invention;

[0030] Figure 4 It is a schematic diagram of the NO time points of each component of the present invention;

[0031] Figure 5 This is a schematic diagram of vWF at each component time point of the present invention;

[0032] Figure 6 This is a schematic diagram of the time points of each component TXB2 of the present invention;

[0033] Figure 7 Schematic diagram of 6-Keto-PGF-1a at various time points of the components of the present invention. DETAILED DESCRIPTION

[0034] The following will be combined with the drawings in the specification of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0035] Embodiment 1:

[0036] Please refer to the attached Figure 1 -Attached Figure 7 The embodiment of the present invention provides a method for protecting vascular endothelial function by combining Qishen Yiqi Drop Pills with atorvastatin, comprising the following steps:

[0037] S1. Selection of experimental subjects: 122 patients with hyperlipidemia were randomly divided into three groups, 40 cases in group A, 40 cases in group B, and 42 cases in group C. One-way analysis of variance and Fisher's exact test were used to compare the differences in basic demographic data among the groups;

[0038] The general data of each group, including gender, age and basal blood lipid levels, had no statistically significant differences (P>0.05) and were comparable at baseline;

[0039] S2. Note the inclusion criteria: meet the diagnostic criteria for hyperlipidemia in the "Expert Consensus on the Diagnosis and Treatment of Dyslipidemia with Integrated Traditional Chinese and Western Medicine", be diagnosed with hyperlipidemia, and be diagnosed with Qi deficiency and blood stasis type according to TCM syndrome differentiation; age 20-80 years old; have no contraindications to the drugs used in this study; have good compliance and can cooperate to complete the study; sign the informed consent form;

[0040] The exclusion criteria include: severe liver and kidney dysfunction, autoimmune diseases, malignant tumors and other diseases; allergic constitution;

[0041] S3. Intervention measures: The control group was given atorvastatin, 20 mg each time, once a day, orally before bedtime; the experimental group A was given Qishen Yiqi dripping pills, 0.5 g each time, 3 times a day, half an hour after meals; the experimental group B was given Qishen Yiqi dripping pills + atorvastatin, with the same usage and dosage as before, and each group was treated with the medicine for 8 consecutive weeks;

[0042] S4. Observation indicators and detection methods: 5 ml of venous blood was drawn from patients at enrollment, 2 weeks, 4 weeks, and 8 weeks of administration, and centrifuged at 3000 r / min at 4°C for 10 min to separate and collect serum, which was then stored at -80°C for later use;

[0043] The specific detection methods are:

[0044] 1. ELISA was used to measure serum endothelin-1 (ET-1), von Willebrand factor (vWF), thromboxane (TXB2), and 6-keto-prostaglandin F-1a (6-Keto-PGF-1a) levels;

[0045] 2. Serum NO level was measured by microplate reader;

[0046] S5. Record reactions: Record drug-related adverse reactions during treatment;

[0047] S6. Statistical analysis: SPSS (24.0) and GraphPad Prism (9.0) software were used for data analysis. Two-way repeated measures analysis of variance was used to determine the effects of different treatments on the index values ​​of the research subjects over time. P < 0.05 was considered statistically significant.

[0048] Effects of the first embodiment:

[0049] Compared with the use of Qishen Yiqi Drops or atorvastatin alone, Qishen Yiqi Drops combined with atorvastatin can better improve the vascular endothelial function of patients with hyperlipidemia, reduce vWF, and correct the imbalance of ET-1 / NO and TXA2 / PGI2, thereby improving vasomotor function, relieving vasospasm, avoiding tissue ischemia and hypoxia, inhibiting thrombosis, delaying the progression of atherosclerosis, and reducing the risk of cardiovascular events. It is beneficial to the long-term prognosis of patients and is a safe and effective treatment option that deserves targeted promotion and application. Relevant indicators can be tested before treatment, and the best drug treatment plan and course of treatment can be selected according to the specific situation.

[0050] Embodiment 2:

[0051] S1. Selection of experimental subjects: 180 patients with hyperlipidemia were selected and randomly divided into three groups, 60 cases in group A, 60 cases in group B, and 60 cases in group C. The Kruskal-Wallis test was used to compare the differences in basic demographic data among the groups;

[0052] S2. Note the inclusion criteria: the age range was adjusted to 25-70 years;

[0053] S3. Intervention measures: The control group was given a standard dose of atorvastatin, 40 mg each time, once a day, orally before bedtime; the experimental group A was given an enhanced dose of Qishen Yiqi Dropping Pills, 2 g each time, 3 times a day, half an hour after meals; the experimental group B was given Qishen Yiqi Dropping Pills (2 g each time, 3 times a day, half an hour after meals) + atorvastatin (40 mg each time, once a day, orally before bedtime). All groups were treated for 16 weeks;

[0054] S4. Observation indicators and detection methods: Add hemodynamic detection, including changes in arterial blood flow velocity and vascular diameter;

[0055] S5. Record drug-related adverse reactions during treatment, as well as the patient's overall satisfaction with treatment;

[0056] S6. Statistical analysis: Add survival analysis to evaluate the effects of different treatments on patients’ quality of life.

[0057] Effects of Example 2: Based on Example 1, the dosage, treatment time, and detection method of patients in Group A and Group B are adjusted to achieve the following effects:

[0058] In group A (Qishen Yiqi Dropping Pills treatment group), due to the enhanced dose of Qishen Yiqi Dropping Pills, there was a significant effect in improving blood lipid levels, especially in reducing total cholesterol and low-density lipoprotein.

[0059] In group B (combined treatment group), the combination of Qishen Yiqi Dropping Pills and atorvastatin had a synergistic effect, further reducing cardiovascular risk, improving blood lipid levels, and enhancing arterial hemodynamic parameters.

[0060] Embodiment three:

[0061] S1. Selection of experimental subjects: 160 patients with hyperlipidemia were randomly divided into two groups, 80 cases in group A and 80 cases in group B. One-way analysis of variance was used to compare the differences in basic demographic data between the groups;

[0062] There was no statistical difference in the general data of each group, ensuring baseline comparability; S2. Note the inclusion criteria: patients with a history of cardiovascular disease were excluded;

[0063] S3. Intervention measures: Group A was given Qishen Yiqi dripping pills (1g each time, 4 times a day, half an hour after meal) + moderate dose of atorvastatin (20mg each time, once a day, orally before bedtime); Group B was given enhanced dose of atorvastatin (80mg each time, once a day, orally before bedtime). Each group was treated with medication for 12 weeks;

[0064] S4. Observation indicators and detection methods: Added the determination of whole blood viscosity and plasma viscosity to evaluate the blood rheological properties;

[0065] S5. Record drug-related adverse reactions and changes in the patient's psychological status during treatment;

[0066] S6. Statistical analysis: A multivariate Cox regression model was introduced to evaluate the impact of multiple factors on the treatment effect.

[0067] Effects of Example 3: Based on Example 1, the dosage, treatment time and detection method of patients in Group A and Group B were adjusted to achieve the following effects:

[0068] Group A (moderate dose of atorvastatin combined with Qishen Yiqi pills) can effectively lower blood lipids and improve blood flow characteristics through Qishen Yiqi pills, which has a positive effect on pathological conditions such as arteriosclerosis;

[0069] Group B (high-dose atorvastatin alone) will perform better in lowering LDL-C (bad cholesterol) and is particularly suitable for patients with extremely high cardiovascular risk.

[0070] Experimental parameter results:

[0071] ET-1

[0072] The results of the variance homogeneity test showed P = 0.710, and the sphericity test result was P < 0.001. The data did not meet the spherical hypothesis. The multivariate test results showed that the ET-1 concentration in each group decreased significantly over time after treatment (P < 0.001), but there was no statistical difference in the effect of different treatments on the change of ET-1 concentration over time (P = 0.174). The results of the inter-subject effect test showed P = 0.119, indicating that there was no significant difference in the effect of different treatments on reducing ET-1 concentration.

[0073] Comparison among the groups at different time points: at 2 weeks of treatment, there was a statistical difference between test group B and control group C; at 4 weeks of treatment, there was a statistical difference between test group B and control group C; at 8 weeks of treatment, there were statistical differences among test group A, test group B and control group C, and there was no statistical difference between test group A and test group B.

[0074] ET-1 in each group before and after treatment

[0075]

[0076] ▲: P<0.05, AorBvsC

[0077] NO

[0078] The results of the variance homogeneity test showed that P = 0.07, and the variance was slightly unequal. The results of the sphericity test were P < 0.05. The results of the multivariate test showed that the NO concentration in each group increased significantly over time after treatment (P < 0.001), and the effects of different treatments on NO concentration and time interaction were statistically significant (P < 0.001). The results of the inter-subject effect test showed that P = 0.038, indicating that different treatments had significant differences in the effects of increasing NO concentration. The difference between group B and group C was statistically significant (P = 0.041) when the groups were compared pairwise.

[0079] Comparison of different time points between groups: There was no statistical difference between the groups at 2 weeks of treatment. At 4 weeks of treatment, there was a statistical difference between the experimental group B and the control group C. At 8 weeks of treatment, there was a statistical difference between the experimental group B and the control group C, and there was also a statistical difference between the experimental group A and the experimental group B.

[0080] NO in each group before and after treatment

[0081]

[0082] ▲: P<0.05, AorBvsC; ●: P<0.05, AvsB

[0083] wxya

[0084] The results of the variance homogeneity test showed P = 0.784, and the sphericity test result was P < 0.001, and the data did not meet the spherical hypothesis. The results of the multivariate test showed that the vWF concentration in each group decreased significantly over time after treatment (P < 0.001), and the effects of different treatments on vWF concentration and time interaction were statistically significant (P < 0.05). The results of the inter-subject effect test showed P = 0.025, indicating that different treatments had significant differences in reducing vWF concentration. The difference between group A and group B was statistically significant (P = 0.024) when the groups were compared pairwise.

[0085] Comparison of different time points between groups: At 2 weeks of treatment, there was a statistical difference between test group A and control group C, and there was also a statistical difference between test group A and test group B. At 4 weeks of treatment, there was a statistical difference between test group A and test group B. At 8 weeks of treatment, there was a statistical difference between test group B and control group C, and there was also a statistical difference between test group A and test group B.

[0086] vWF in each group before and after treatment

[0087]

[0088] ▲: P<0.05, AorBvsC;; ●: P<0.05, AvsB

[0089] TXB2

[0090] The results of the variance homogeneity test showed P = 0.740. The results of the sphericity test were P < 0.001, and the data did not meet the spherical hypothesis. The results of the multivariate test showed that the TXB2 concentration in each group decreased significantly over time after treatment (P < 0.001), and the effects of different treatments on TXB2 concentration and time interaction were statistically significant (P < 0.001). The results of the inter-subject effect test showed P = 0.138, indicating that there was no significant difference in the effects of different treatments on reducing TXB2 concentration.

[0091] Comparison of different time points between groups: There was no statistical difference between the groups at 2 weeks of treatment. At 4 weeks of treatment, there was a statistical difference between the test group A and the control group C, and there was a statistical difference between the test group B and the control group C. At 8 weeks of treatment, there was a statistical difference between the test group A and the control group C, and there was a statistical difference between the test group B and the control group C.

[0092] TXB2 in each group before and after treatment

[0093]

[0094]

[0095] ▲: P<0.05, AorBvsC

[0096] 6-Keto-PGF-1a

[0097] The results of the variance homogeneity test showed that P = 0.649. The results of the sphericity test were P = 0.187 > 0.05. The results of the within-subject effect test showed that the concentration of 6-Keto-PGF-1a in each group increased significantly over time after treatment (P < 0.001). The effects of different treatment methods on the concentration of 6-Keto-PGF-1a and the interaction with time were statistically significant (P < 0.05). The results of the between-subject effect test showed that P = 0.596, indicating that there was no significant difference in the effect of different treatment methods on increasing the concentration of 6-Keto-PGF-1a.

[0098] Comparison of different time points between groups: At 2 weeks of treatment, there was no statistical difference between the groups. At 4 weeks of treatment, there was no statistical difference between the groups. At 8 weeks of treatment, there was a statistical difference between the experimental group B and the control group C, and there was a statistical difference between the experimental group B and the experimental group A.

[0099] 6-Keto-PGF-1a in each group before and after treatment

[0100]

[0101]

[0102] ▲: P<0.05, AorBvsC; ●: P<0.05, AvsB

[0103] Regarding the above experimental results:

[0104] Vascular endothelial cells act as a barrier between the vascular wall and the blood. As an important endocrine organ of the body, they can synthesize and secrete a variety of vasoactive substances. They can regulate vasodilation and hemodynamics by maintaining a balance between vasoconstrictor factors and vasodilator factors. They also inhibit platelet adhesion, aggregation and thrombosis. Endothelial dysfunction is the initiating factor of many diseases. It not only promotes the formation of AS, but also plays a decisive role in the progression of AS. Protecting endothelial function has become one of the important strategies for the treatment of cardiovascular diseases.

[0105] NO and ET-1 are important indicators of endothelial function. They are vasodilator and vasoconstrictor factors synthesized by endothelial cells, respectively. Under normal circumstances, NO / ET-1 is in a dynamic balance, dynamically regulating vascular elasticity and maintaining vascular vasoconstriction. Hyperlipidemia causes hemodynamic changes, and the turbulence and shear stress generated cause endothelial damage, thereby causing changes in the content of endothelial-related factors. Endothelial dysfunction can cause an imbalance in the NO / ET-1 ratio, an increase in ET-1 levels, and a decrease in NO levels, leading to abnormal vascular vasoconstriction and hypoxia and ischemia. The more severe the endothelial damage, the higher the ET-1 content and the lower the NO content. Increased ET-1 levels can accelerate the process of atherosclerosis. Recent studies have shown that ET-1 is associated with diseases such as atherosclerosis, hypertension, and vasospasm. Increased ET-1 concentrations have also been found in local atherosclerotic plaques. Increased ET-1 levels are a risk factor for poor prognosis in patients with cardiovascular disease. NO has opposite effects to ET-1 and can inhibit vasoconstriction, leukocyte adhesion and platelet aggregation, and vascular smooth muscle cell proliferation, thereby delaying the progression of atherosclerosis.

[0106] This study showed that the three treatments of Qishen Yiqi Dropping Pills, atorvastatin, and Qishen Yiqi Dropping Pills combined with atorvastatin can effectively reduce ET-1 in patients with hyperlipidemia, but overall there was no significant difference in reducing ET-1 levels among the three treatments. Comparison between the groups at different time points showed that at 2 weeks of treatment, the combined medication group was better than the atorvastatin group; at 4 weeks of treatment, the combined medication group was better than the atorvastatin group; at 8 weeks of treatment, the combined medication group was better than the atorvastatin group, and the Qishen Yiqi Dropping Pills group was better than the atorvastatin group. This indicates that Qishen Yiqi Dropping Pills combined with atorvastatin can reduce ET-1 in patients with hyperlipidemia, and the effect may be better than atorvastatin alone. The difference was reflected in 2 weeks of treatment, and the efficacy advantage was maintained at 4 and 8 weeks of treatment. From 2 weeks to 8 weeks, the effect of Qishen Yiqi Dropping Pills gradually became stronger than atorvastatin.

[0107] This study shows that the three treatments of Qishen Yiqi Dropping Pills, atorvastatin, and Qishen Yiqi Dropping Pills combined with atorvastatin can effectively increase NO. The effects of different treatments on NO concentrations will change over time. Overall, there are significant differences in the three treatments in increasing NO levels: the combined medication group is better than the atorvastatin group. Comparison of time points between groups: at 4 weeks of treatment, the combined medication group is better than the atorvastatin group, and at 8 weeks of treatment, the combined medication group is better than the atorvastatin group, and the combined medication group is better than the Qishen Yiqi Dropping Pills group. This shows that Qishen Yiqi Dropping Pills combined with atorvastatin can significantly increase NO, and the effect is better than atorvastatin alone. The difference is reflected in 4 weeks of treatment, and the efficacy advantage is more obvious at 8 weeks of treatment.

[0108] After treatment in each group, ET-1 decreased and NO increased, indicating that the three treatment methods can regulate the imbalance of ET-1 / NO in patients with hyperlipidemia, improve endothelial function, reduce the contraction and spasm of diseased blood vessels, delay the progression of atherosclerosis, and reduce the risk of cardiovascular events. Combination therapy has the best effect.

[0109] vWF is a glycoprotein synthesized and stored by vascular endothelial cells. It is one of the most important endogenous vasoconstrictor factors and plays an important regulatory role in thrombosis formation and progression. In patients with hyperlipidemia, increased blood lipids cause changes in hemodynamics, generate turbulence and shear stress, and cause functional and anatomical damage to the arterial intima. The vWF stored in Weibe l-pa lade bodies is excessively released, causing a significant increase in the vWF content in plasma, promoting platelet adhesion and aggregation. The vWF content is positively correlated with the severity of vascular endothelial damage and atherosclerosis, and is considered to be the most specific indicator of vascular endothelial damage. Studies have confirmed that ET-1, NO, and vWF are markers for judging vascular endothelial function, which antagonize each other and can indicate the degree of arterial vascular obstruction.

[0110] This study shows that the three treatments of Qishen Yiqi Dropping Pills, atorvastatin, and Qishen Yiqi Dropping Pills combined with atorvastatin can effectively reduce vWF in patients with hyperlipidemia. The effects of different treatments on vWF concentrations will change over time. Overall, there are significant differences in reducing vWF levels among the three treatments: the combined medication group is better than the Qishen Yiqi Dropping Pills group. Comparison between groups at different time points showed that at 2 weeks of treatment, the combined medication group was better than the Qishen Yiqi Dropping Pills group, and the atorvastatin group was better than the Qishen Yiqi Dropping Pills group. At 4 weeks of treatment, the combined medication group was better than the Qishen Yiqi Dropping Pills group. At 8 weeks of treatment, the combined medication group was better than the atorvastatin group, and the combined medication group was better than the Qishen Yiqi Dropping Pills group. This indicates that Qishen Yiqi Dropping Pills combined with atorvastatin can significantly reduce vWF in patients with hyperlipidemia, reduce vascular endothelial damage, and inhibit thrombosis. The effect is better than Qishen Yiqi Dropping Pills alone. The difference is obvious after 2 weeks of treatment, and the efficacy advantage is still maintained after 4 and 8 weeks of treatment. Compared with the effect of atorvastatin, the effects of Qishen alone and Qishen combined with atorvastatin are more stable.

[0111] TXA2 is an endogenous vasoactive substance synthesized and released by platelets, which has the effect of promoting vasoconstriction and platelet aggregation. PGI2 is a vasoactive substance secreted by vascular endothelial cells, which has the effect of vasodilation and inhibiting platelet aggregation. Under normal circumstances, TXA2 / PG I2 is in a dynamic balance, playing an important role in maintaining vasoconstriction and smooth blood circulation. 6-Keto-PGF-1a and TXB2 are stable metabolites of PGI2 and TXA2, and their concentrations are usually used clinically to indicate the level of PGI2 and TXA2 in the body. Dyslipidemia can increase the release of TXB2 and reduce the release of 6-Keto-PGF-1a, leading to an imbalance of TXB2 / 6-Keto-PGF-1a, inducing thrombosis and vasoconstriction, resulting in reduced blood flow, and then ischemia and hypoxia in the body.

[0112] This study showed that the three treatments of Qishen Yiqi Dropping Pills, atorvastatin, and Qishen Yiqi Dropping Pills combined with atorvastatin can effectively reduce TXB2 in patients with hyperlipidemia. The effects of different treatments on TXB2 concentrations will change over time. Overall, there is no significant difference in reducing TXB2 levels among the three treatments. Comparison between groups at different time points showed that at 4 weeks of treatment, the combined medication group was better than the atorvastatin group, and the Qishen Yiqi Dropping Pills group was better than the atorvastatin group. At 8 weeks of treatment, the combined medication group was better than the atorvastatin group, and the Qishen Yiqi Dropping Pills group was better than the atorvastatin group. This shows that Qishen Yiqi Dropping Pills combined with atorvastatin can effectively reduce TXB2 in patients with hyperlipidemia, and the effect may be better than atorvastatin alone. The difference was seen at 4 weeks of treatment, and the efficacy advantage was maintained at 8 weeks of treatment. The efficacy of Qishen Yiqi Dropping Pills alone may also be better than atorvastatin.

[0113] This study shows that the three treatments of Qishen Yiqi Dropping Pills, atorvastatin, and Qishen Yiqi Dropping Pills combined with atorvastatin can effectively increase 6-Keto-PGF-1a in patients with hyperlipidemia, suggesting that the effects of different treatments on 6-Keto-PGF-1a concentrations will change over time. Overall, there was no significant difference in the three treatments in increasing 6-Keto-PGF-1a levels. Comparison between the groups at different time points showed that at 8 weeks of treatment, the combined medication group was superior to the atorvastatin group, and the combined medication group was superior to the Qishen Yiqi Dropping Pills group. This shows that after 8 weeks of continuous use, Qishen Yiqi Dropping Pills combined with atorvastatin can better increase 6-Keto-PGF-1a.

[0114] After treatment, TXB2 decreased and 6-Keto-PGF-1a increased, indicating that Qishen Yiqi Drops combined with atorvastatin can better correct the imbalance of TXA2 / PGI2, relieve vasospasm, inhibit platelet aggregation, improve vasomotor function, and avoid tissue ischemia and hypoxia.

[0115] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A method for protecting vascular endothelial function by combining Qishen Yiqi Drop Pills with atorvastatin, characterized in that: The following steps are involved: S1. Selection of experimental subjects: Appropriate patients with hyperlipidemia were selected and divided into groups. One-way analysis of variance and Fisher's exact test were used to compare the differences in basic demographic data between the groups; S2. Pay attention to the inclusion criteria: meet the medical experiment criteria, meet the age criteria, meet the compliance criteria, and also pay attention to the exclusion criteria; S3. Intervention measures: The control group was given atorvastatin according to the medication regulations of the control group; the experimental group A was given Qishen Yiqi dripping pills according to the medication regulations of group A; the experimental group B was given Qishen Yiqi dripping pills + atorvastatin, with the same usage and dosage as before, and each group took the medicine for 8-9 weeks; S4. Observation indicators and detection methods: At enrollment, 2-3 weeks after administration, 4-5 weeks after administration, and 8-9 weeks after administration, extract patient characteristics and save them for future use, and use specific detection methods; S5. Record reactions: Record drug-related adverse reactions during treatment; S6. Statistical analysis: Data analysis was performed using SPSS and GraphPad Prism software. Two-way repeated measures analysis of variance was used to determine the effects of different treatments on the index values ​​of the research subjects over time. P < 0.05 was considered statistically significant.

2. The method for protecting vascular endothelial function by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: In step S1, appropriate hyperlipidemia patients are selected and grouped as follows: 122-130 hyperlipidemia patients are selected and randomly divided into three groups, 40-42 cases in group A, 40-44 cases in group B, and 42-46 cases in group C.

3. The method for protecting vascular endothelial function by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The basic demographic data mentioned in step S1 specifically include gender, age and basal blood lipid levels. At the same time, the data should be compared to have no statistically significant differences and have baseline comparability.

4. The method for protecting vascular endothelial function by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The medical experimental standards mentioned in step S2 specifically include: meeting the diagnostic standards for hyperlipidemia, being diagnosed with hyperlipidemia, and belonging to the Qi deficiency and blood stasis type according to TCM syndrome differentiation.

5. The method for protecting vascular endothelial function by combining Qishen Yiqi Dropping Pills with atorvastatin according to claim 1, characterized in that: The age standard mentioned in step S2 is specifically: age 20-80 years old.

6. The method for protecting vascular endothelial function by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The compliance standards mentioned in step S2 are specifically: no contraindications to the drugs used in this study, good compliance, ability to cooperate in completing the study, and signing of the informed consent form.

7. The method for protecting vascular endothelial function by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The exclusion criteria mentioned in step S2 are specifically: severe liver and kidney dysfunction, autoimmune diseases, malignant tumors; allergic constitution.

8. The method for protecting vascular endothelial function by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The specific medication regulations for the control group mentioned in step S3 are: 20-30 mg each time, once a day, orally before bedtime; the specific medication regulations for group A mentioned in step S3 are: 0.5-0.6 g each time, 3 times a day, half an hour after a meal.

9. The method for protecting vascular endothelial function by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The extraction of patient characteristics and storage for later use mentioned in step S4 specifically includes: drawing 5-6 ml of venous blood from the patient, centrifuging at 3000 r / min at 4°C for 10-15 min, separating and collecting serum, and storing it at -80--90°C for later use.

10. The method for protecting vascular endothelial function by combining Qishen Yiqi Dropping Pills with atorvastatin according to claim 1, characterized in that: The specific detection methods in step S4 include: ELISA method to determine serum endothelin-1, von Willebrand factor, thromboxane, 6-keto-prostaglandin F-1a levels; microplate enzyme reader to determine serum NO level.

Citation Information

Patent Citations

  • Medicinal composition for preventing and treating atherosclerosis

    CN102125567A